Advocates Call For STLD Plan Limits After Report Confirms High Costs

Beneficiary advocates point to a new analysis that verifies long-standing concerns that patients who buy lower premium short-term limited duration (STLD) are at financial risk should they need to use their coverage, and they are using the analysis to re-up their calls for federal and state action to limit or ban the plans. The Leukemia and Lymphoma Society commissioned the Milliman, Inc. report, which looked at the costs for consumers treated for lymphoma, heart attacks, lung cancer, diabetes and mental...